Explore insights from bit.bio Senior Scientist Andreas as he shares his experiences judging the iGEM competition.
17.10.2024
bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming Technology
The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the bro...
bit.bio featured in Tech Nation's Future Fifty Report
bit.bio has been named one of the UK's most successful tech companies in the prestigious Future Fifty report. Discover how our syn...
Interview with Roger Pedersen for Stem Cell Awareness Day
Today we celebrate Stem Cell Awareness Day and salute all of our peers working to realise the therapeutic potential of stem cell-d...
bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference
bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference.
bit.bio Honoured as Life Science Innovation at the 2024 Business Weekly Awards
bit.bio Wins Honours for Innovation in Synthetic Biology and Exceptional Business Growth.
bit.bio expands Executive Team with appointment of Przemek Obloj as Chief Financial Officer
bit.bio appoints new Chief Financial Officer, Przemek Obloj
bit.bio launches 16 disease models for neurodegenerative disease
bit.bio launches panel of 16 neurodegenerative disease models for research and drug discovery in Alzheimer’s and Parkinson’s disea...
Sustainability Report
Presenting our first annual sustainability report, detailing our Corporate Sustainability Strategy and progress towards our aligne...